Learn how ESR1 mutations drive endocrine resistance and how FDA-approved oral SERDs improve outcomes, shaping smarter sequencing and future combos.
Oral Selective Estrogen Receptor Degraders in HR-Positive/HER2- Negative Metastatic Breast Cancer: Clinical Insights on Sequencing, Biomarkers, and Emerging Combinations
Advertisement
Advertisement
Trending on OncLive
1
Ziftomenib Plus 7+3 Elicits Durable Responses in Newly Diagnosed NPM1-Mutant and KMT2A-Rearranged AML
2
Gilteritinib Yields Comparable Efficacy vs Midostaurin in Newly Diagnosed FLT3-Mutated AML but Fails to Meet Phase 3 Primary End Point
3
Dr Voorhees on Efficacy Data for Talquetamab-Based Combos in R/R Myeloma From MonumenTAL-3
4
Tuspetinib Plus Venetoclax and Azacitidine Is Safe and Effective Across Molecular Subgroups in Newly Diagnosed AML
5